CEDAR KNOLLS, N.J — Moberg Pharma AB has started shipping a new formulation of its Kerasal Nail product to the U.S. market.
Moberg Pharma AB has started shipping a new formulation of its Kerasal Nail product to the U.S. market.
Kerasal Nail, which is available at more than 30,000 retail outlets in the United States, is the market-leading product in the over-the-counter fungal nail category.
The new formula is more user-friendly and facilitates nail penetration, according to the company, which has applied for patent protection (with a projected expiration date of 2034) for the product.
"We are very pleased to announce the launch of the improved formula," said Moberg Pharma chief executive officer Peter Wolpert. "The new and improved Kerasal Nail demonstrates the value of our development approach, which continues to deliver innovative products with unique benefits to consumers."
